The activity of the Complementary Medicine Office from the Research & Development Department of Romvac Company S.A.
Starting with 2016, specific Y-immunoglobulin therapy is recommended within the Imunoinstant Complementary Medicine Office, which is part of the Romvac Company S.A. Research & Development Department.
Currently, the cabinet has a number of over 5000 patients, with a wide range of diseases, including:
patients with type I or type II diabetes;
patients with palmar-plantar psoriasis with nail involvement;
patients with nail psoriasis;
patients with generalized psoriasis;
patients with bullous epidermolysis;
patients with urinary infection caused by Escherichia coli, Klebsiella spp., Proteus mirabilis, Enterococcus faecalis, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus grup B.
patients with genital infection caused by Candida spp., Escherichia coli, Enterococcus faecalis, Klebsiella spp., Streptococcus grup B., Staphylococcus , HPV (9 tulpini), Herpes Simplex tip 1 (HSV 1);
patients with herpes infection caused by Herpes Simplex (HSV 1);
patients with gastric infection caused by Helicobcater pylori;
patients with gastrointestinal infection caused by Clostridium difficile, Escherichia coli;
patients with periodontists infection caused by Staphylococcus spp., Streptococcus spp.;
patients with acne of various forms caused by Staphylococcus aureus;
patients with different type of dermatitis caused by infection with Staphylococcus aureus;
patients with infected wounds caused by Staphylococcus aureus MRSA, Pseudomonas aeruginosa, Klebsiella spp., Candida spp., Escherichia coli;
patients with respiratory infection caused by Streptococcus pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa;